Transgenic Group Inc. (2342) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Transgenic Group Inc. (2342:JPX), powered by AI.

Current Price
¥217
P/E Ratio
-3.3
Market Cap
3.6B
Sector
Healthcare
What is the Transgenic Group Inc. stock price forecast?

Transgenic Group Inc. is currently trading at ¥217. View real-time AI analysis on Alpha Lenz.

What is Transgenic Group Inc. insider trading activity?

View the latest insider trading data for Transgenic Group Inc. on Alpha Lenz.

What is Transgenic Group Inc.'s P/E ratio?

Transgenic Group Inc.'s P/E ratio is -3.3.

Transgenic Group Inc.

JPX · 2342
¥217+5(+2.36%)Market closedJPX regular session 09:00–15:00 JST
Ask about Transgenic Group Inc.'s future dividend policy...
Alpha Chat Insight

Transgenic Group Inc. trades at a P/E of -3.3 (undervalued) with modest ROE of -20.4%.

Ask for details

Company Overview

Transgenic Group Inc. is a biotechnology company specializing in genetic engineering solutions across various sectors. The primary function of Transgenic Group Inc. is to develop and commercialize genetically modified organisms (GMOs) that enhance agricultural productivity, improve healthcare outcomes, and contribute to sustainable industrial processes. This company's operations significantly impact the agriculture industry by producing crop variants that exhibit increased resistance to pests and diseases and enhanced nutritional profiles. Additionally, in the healthcare sector, Transgenic Group Inc. focuses on advancements in gene therapy and personalized medicine by leveraging its expertise in genetic manipulation. The innovative technologies developed by the company have the potential to cater to increasing global demands in food security and precision medicine. Within the financial market, Transgenic Group Inc. represents a vital entity for investors interested in cutting-edge biotechnology and genetics-based solutions. Its contributions are essential for addressing global challenges related to food supply, health improvements, and environmental sustainability, making it a key player in advancing life sciences.

CEOMr. Kenji Fukunaga
SectorHealthcare
IndustryBiotechnology
Employees241

Company Statistics

FY 2025

Profile

¥3,609,397,673Market Cap
¥13,005,126,000Revenue
0.00Shares Out
241Employees

Margins

16.66%Gross
-0.58%EBITDA
-2.00%Operating
-5.20%Pre-Tax
-8.39%Net

Valuation

-3.31P/E
0.76P/B
0.28EV/Sales
-49.39EV/EBITDA
-44.37P/FCF

Growth (CAGR)

1.12%Rev 3Yr
3.32%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-11.24%ROA
-20.45%ROE
-6.59%ROIC

Financial Health

¥2,555,397,000Cash & Cash Equivalents
¥2,174,823,000Net Debt
97.41%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Transgenic Group Inc. (ticker: 2342) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 241 employees. Market cap is $3.6B.

The current price is 217 with a P/E ratio of -3.31x and P/B of 0.76x.

ROE is -20.45% and operating margin is -2.00%. Annual revenue is $13.0B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Transgenic Group Inc. (2342) Stock Forecast 2026 ¥217 — Price, Financials & Analyst Targets | Alpha Lenz